Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in advanced solid tumors
NCT02054806Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2014
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in solid tumor, sponsored by Merck & Co. Primary endpoint: Overall Response Rate up to 86 months. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02054806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054806.